---
layout: post
title: "** 1B-LSD: Understanding the Chemistry, History, and Status of the Lysergamide Derivative

**"
description: "** Explore 1B-LSD (1-butyryl-LSD), a prominent lysergamide research chemical and analogue of LSD. Learn about its prodrug mechanism, legal status, and chemical properties in this comprehensive guide.

**"
image: "https://images.unsplash.com/featured/?**%201B-LSD%0A%0A**"
date: 2025-12-28T11:03:55.639Z
permalink: /2025/12/28/1b-lsd-understanding-the-chemistry-history-and-status-of-the.html
---

![** Chemical diagram illustrating the butyryl group attached to the LSD molecular structure (1B-LSD).

**](https://images.unsplash.com/featured/?**%201B-LSD%0A%0A**)

**

<h2>Introduction to 1B-LSD: A Modern Lysergamide Analogue</h2>

<p>The landscape of psychoactive compounds is constantly evolving, driven by scientific exploration and, often, regulatory evasion. Among the substances that have emerged from this dynamic environment is <strong>1B-LSD</strong>, formally known as 1-butyryl-LSD. This compound belongs to the lysergamide family, a classification shared by its famous predecessor, lysergic acid diethylamide (LSD).</p>

<p>1B-LSD is categorized as a novel psychoactive substance (NPS) or a "research chemical." While it shares a fundamental structural backbone with LSD, it incorporates a modification—a butyryl group—at the indole nitrogen of the lysergic acid moiety. This seemingly minor chemical alteration is responsible for defining its unique pharmacological profile, its classification as an acylated derivative, and, most critically, its legal status in jurisdictions where LSD is strictly controlled.</p>

<p>The interest surrounding 1B-LSD stems primarily from the observation that many N1-substituted lysergamides function as prodrugs, meaning they are metabolized by the body into the parent compound (LSD) before they exert their primary effects. As a result, 1B-LSD has been widely sold online as a designer drug, primarily intended for chemical research or analytical purposes, but often acquired by individuals seeking psychedelic experiences.</p>

<h2>The Chemistry of 1B-LSD: 1-Butyryl-LSD</h2>

<p>To fully understand 1B-LSD, one must look closely at its molecular architecture. The lysergamide core is derived from lysergic acid, a naturally occurring alkaloid produced by the ergot fungus. The ‘LSD’ component refers to the diethylamide group attached to carbon 8 of the ergoline structure. 1B-LSD maintains this core structure but distinguishes itself through the addition of a four-carbon butyryl group (C₄H₇O) situated at the nitrogen atom located at position 1 of the indole ring. Hence the name: <strong>1-butyryl-LSD</strong>.</p>

<p>Chemically, this compound is classified as a synthetic acylated derivative. The butyryl group is an acyl group derived from butyric acid. This substitution pattern (N1 acylation) is common among modern lysergamide analogues developed since the early 2010s, including 1P-LSD (1-propionyl-LSD) and ALD-52 (1-acetyl-LSD). These substitutions are designed to maintain high structural similarity to LSD while technically creating a novel compound.</p>

<h3>Nomenclature Breakdown:</h3>
<ul>
    <li><strong>1-Position:</strong> Indicates the location of the substitution on the ergoline ring’s indole nitrogen.</li>
    <li><strong>Butyryl:</strong> Identifies the specific chemical group—a four-carbon chain—attached at that position.</li>
    <li><strong>LSD:</strong> Refers to the underlying lysergic acid diethylamide core structure.</li>
</ul>

<p>The precise synthesis of 1B-LSD involves reacting lysergic acid diethylamide with a source of the butyryl group, typically butyryl chloride or butyric anhydride, under controlled chemical conditions. The resulting product is often synthesized and distributed in the form of tartrate or hemi-succinate salts to improve stability and solubility, which is typical for compounds in the lysergamide class.</p>

<h2>The Prodrug Hypothesis: Metabolism and Activity</h2>

<p>One of the most compelling scientific aspects of <strong>1B-LSD</strong>, and the primary reason for its high market demand, is the strong evidence suggesting it operates as a prodrug. A prodrug is a biologically inactive compound that, upon administration, is metabolized by the body into an active drug. In the case of 1B-LSD, the hypothesis is that the molecule must be hydrolyzed—cleaving the butyryl group—to yield the biologically active parent compound, LSD.</p>

<p>The cleavage of the butyryl group is believed to occur primarily through the action of ubiquitous enzymes known as carboxylesterases. These enzymes are found throughout the body, particularly in the liver, plasma, and gastrointestinal tract. Once the butyryl group is removed, the resulting molecule is indistinguishable from standard LSD, which then binds to the serotonin receptors (particularly the 5-HT₂A receptor) to produce its characteristic psychedelic effects.</p>

<p>Scientific studies focused on N1-substituted lysergamides, particularly 1P-LSD, have provided significant pharmacological backing for this mechanism. Research utilizing human serum and liver microsomes confirmed the rapid *in vitro* conversion of these analogues to LSD. While the specific kinetics for 1B-LSD might differ slightly due to the longer carbon chain (four carbons in 1B-LSD vs. three carbons in 1P-LSD), the underlying metabolic pathway remains the same.</p>

<p>The prodrug mechanism may account for certain subjective differences reported by users compared to standard LSD, such as a slightly slower onset time. Since the body needs time to metabolize the substance, the appearance of the full effects may be marginally delayed, resulting in a perceived difference in the onset "curve" or duration of action. However, once converted, the overall pharmacological action is effectively identical to that of LSD.</p>

<h2>History, Availability, and the Rise of Designer Drugs</h2>

<p>The emergence of <strong>1B-LSD</strong> is intrinsically linked to the global phenomenon of novel psychoactive substances (NPS) and the designer drug market. Following the successful introduction and market saturation of analogues like 1P-LSD, chemists sought to develop new N1-substituted derivatives that would not yet be explicitly prohibited by evolving drug legislation.</p>

<p>1B-LSD first appeared on the illicit market around 2016 and quickly gained attention alongside other new lysergamides. Its primary distribution method has historically been via online vendors, who often market the substance as a "research chemical" or "for forensic purposes only" to circumvent legal restrictions, usually in the form of blotter paper or liquid solutions.</p>

<p>The existence of these analogues highlights a key challenge for drug enforcement agencies: the speed and ease with which minor chemical modifications can create substances that are functionally similar to controlled drugs but technically fall outside the scope of current legislation. This creates a regulatory "grey area" that compounds like 1B-LSD exploit until specific legislation, or broad analogue laws, are enacted.</p>

<h2>Pharmacological Data and Research Limitations</h2>

<p>Despite the popularity of <strong>1B-LSD</strong>, it is crucial to emphasize that formal, extensive clinical and toxicological studies—the kind typically required for pharmaceutical approval—have not been conducted. Most of the information regarding its effects, potency, duration, and safety profile is anecdotal, extrapolated from the known effects of LSD, or derived from limited *in vitro* analysis.</p>

<p>Anecdotal reports often place 1B-LSD’s potency slightly below or equivalent to that of 1P-LSD, and generally comparable to LSD itself, once the prodrug conversion is complete. The commonly reported duration of effects tends to align with LSD (8 to 12 hours), which is consistent with the hypothesis that the active agent is ultimately LSD.</p>

<p>However, the lack of comprehensive human safety data presents significant risks. The long-term effects of chronic use, potential neurotoxicity, and specific interaction profiles with other medications are poorly understood. Furthermore, because these compounds are synthesized in unregulated laboratories, purity and consistency are never guaranteed, introducing the additional risk of contamination with harmful byproducts.</p>

<h2>The Legal Status and Regulatory Response to 1B-LSD</h2>

<p>The legal status of <strong>1B-LSD</strong> is highly complex, varying dramatically across international borders. Because it is a novel compound, it often exists in a legislative grey zone until authorities specifically schedule or ban it.</p>

<p>In many jurisdictions, 1B-LSD is not specifically named under controlled substance acts. Instead, its legal status is determined by broader legislation:</p>

<ul>
    <li><strong>Analogue Acts (e.g., United States):</strong> In the U.S., the Federal Analogue Act allows compounds substantially similar in chemical structure and pharmacological effect to a Schedule I controlled substance (like LSD) to be treated as if they were also Schedule I drugs. Since 1B-LSD is considered an analogue of LSD, it is generally illegal under federal law if intended for human consumption.</li>
    <li><strong>Generic Bans (e.g., United Kingdom):</strong> Countries like the U.K. utilize blanket bans or specific NPS legislation, such as the Psychoactive Substances Act (PSA) 2016. This type of law targets any substance capable of producing a psychoactive effect, regardless of its specific chemical structure, effectively banning 1B-LSD.</li>
    <li><strong>Specific Scheduling (e.g., Germany):</strong> Other nations explicitly schedule new lysergamide analogues. For instance, Germany added several N1-substituted lysergamides, including 1B-LSD, to its controlled substances list to close loopholes.</li>
</ul>

<p>Due to the aggressive regulatory response globally to the proliferation of designer drugs, the legal window of opportunity for compounds like 1B-LSD is rapidly shrinking. Researchers, chemists, and consumers must maintain vigilance regarding evolving legal frameworks, as the classification and regulation of these chemicals are subject to frequent change.</p>

<h2>Conclusion: An Evolving Research Chemical</h2>

<p><strong>1B-LSD</strong> represents a sophisticated example of modern chemical synthesis aimed at modifying existing psychoactive compounds. As an acylated lysergamide derivative and likely prodrug to LSD, it holds significant interest in pharmacology for studying the metabolism of N1-substituted ergoline derivatives.</p>

<p>However, its status as a widely distributed research chemical necessitates caution. The lack of standardized toxicological data and the inherent risks associated with unregulated production mean that its long-term safety profile remains unknown. As regulatory bodies worldwide continue to refine their approach to novel psychoactive substances, the legal landscape surrounding 1B-LSD and its analogues will undoubtedly continue to tighten, pushing these compounds further into illegality.</p>

---

### Read Next
- [John Williams Farm](https://yacine-l.github.io/hot-info/2025/12/27/john-williams-farm.html)